Filtered By:
Cancer: Cancer
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 347 results found since Jan 2013.
Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases —a phase II study
ConclusionsPanitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%. These data are insufficient to widen the indication of panitumumab from the unresectable setting to the setting of resectable CLM.
Source: Frontiers in Oncology - August 9, 2023 Category: Cancer & Oncology Source Type: research
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment
Semin Thromb Hemost DOI: 10.1055/s-0043-1771270Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke in cancer patients. Novel biomarkers, including coagulation, platelet and endothelial markers, cell-free DNA, and extracellular vesicles are being investigated for their potentia...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2023 Category: Hematology Authors: Costamagna, Gianluca Navi, Babak B. Beyeler, Morin Hottinger, Andreas F. Alberio, Lorenzo Michel, Patrik Tags: Review Article Source Type: research
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
CONCLUSIONS: Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.PMID:37477938 | DOI:10.1158/1078-0432.CCR-23-0388
Source: Clinical Cancer Research - July 21, 2023 Category: Cancer & Oncology Authors: Qingsheng Xu Kaiyuan Huang Xiangqi Meng Yuxiang Weng Luyuan Zhang Linghao Bu Xiujue Zheng Jinquan Cai Renya Zhan Qun Chen Source Type: research
Stroke death in patients receiving radiation for head and neck cancer in the modern era
CONCLUSIONS: While radiotherapy for head and neck cancer increases the hazard of stroke death, this is reduced in the modern era and remains a very small absolute risk.PMID:37397363 | PMC:PMC10313411 | DOI:10.3389/fonc.2023.1111764
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Sara J Hardy Sanjukta Bandyopadhyay Hongmei Yang Annalynn Williams Abdi Gudina Michael A Cummings Hong Zhang Deepinder P Singh Yuhchyau Chen Nimish A Mohile Michelle C Janelsins Michael T Milano Source Type: research
The Incident Ocular Diseases Related to Chemotherapy in Cancer Patients are Associated with Increasing Risk of Incident Stroke
CONCLUSIONS: Incident ocular diseases related to chemotherapy were associated with a significantly higher risk of stroke.PMID:37229341 | PMC:PMC10203719 | DOI:10.6515/ACS.202305_39(3).20221005A
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Kai-Chun Cheng Hung-Pin Tu Tsung-Hsien Lin Kai-Hung Cheng Source Type: research
